Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Adakveo Fails A Phase III Study
Executive Summary
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
You may also be interested in...
Novartis Measures Malaria Success On Impact Rather Than Money
The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.
Sickle Cell Drug Development Gains Momentum Across Disease Spectrum
The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options.
Sickle Cell Gene Therapy Cost Effectiveness Draws Scrutiny At ASH
According to a study presented at the American Society of Hematology, based on existing gene therapy prices, equitable use of sickle cell disease gene therapy requires expanding into patients who are younger and have less severe disease.